Ted Love, Global Blood Therapeutics CEO
Updated: Pfizer scoops up Global Blood Therapeutics and its sickle cell therapies for $5.4B
Pfizer is dropping $5.4 billion to acquire Global Blood Therapeutics.
Just ahead of the weekend, word got out that Pfizer was close to clinching a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.